Equities research analysts expect that OPKO Health, Inc. (NASDAQ:OPK) will announce $304.07 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for OPKO Health’s earnings, with estimates ranging from $298.60 million to $307.10 million. OPKO Health posted sales of $428.10 million during the same quarter last year, which suggests a negative year-over-year growth rate of 29%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 4th.
According to Zacks, analysts expect that OPKO Health will report full-year sales of $1.58 billion for the current financial year, with estimates ranging from $1.54 billion to $1.61 billion. For the next fiscal year, analysts expect that the business will report sales of $1.31 billion, with estimates ranging from $1.16 billion to $1.44 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for OPKO Health.
OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, July 29th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.05). OPKO Health had a net margin of 3.71% and a return on equity of 4.21%. The business had revenue of $442.40 million for the quarter, compared to analyst estimates of $457.57 million.
In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the business’s stock in a transaction on Tuesday, September 14th. The shares were acquired at an average cost of $3.46 per share, with a total value of $346,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $10,618,570.46. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 41.47% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP increased its position in shares of OPKO Health by 129.9% in the 1st quarter. Quantbot Technologies LP now owns 7,294 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 4,122 shares during the last quarter. Eqis Capital Management Inc. acquired a new stake in shares of OPKO Health in the second quarter worth approximately $41,000. Virtu Financial LLC acquired a new position in OPKO Health during the first quarter valued at approximately $48,000. Profund Advisors LLC acquired a new position in shares of OPKO Health during the first quarter worth $52,000. Finally, Beacon Pointe Advisors LLC bought a new stake in shares of OPKO Health in the second quarter worth $51,000. Institutional investors own 27.56% of the company’s stock.
OPK stock traded up $0.07 during trading on Monday, hitting $3.80. 52,583 shares of the company’s stock traded hands, compared to its average volume of 5,145,085. The company has a quick ratio of 1.36, a current ratio of 1.80 and a debt-to-equity ratio of 0.11. OPKO Health has a 52 week low of $3.02 and a 52 week high of $6.27. The stock has a fifty day moving average price of $3.72 and a two-hundred day moving average price of $3.83. The stock has a market capitalization of $2.59 billion, a price-to-earnings ratio of 34.46 and a beta of 1.75.
About OPKO Health
OPKO Health, Inc, is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment include clinical laboratory operations of BioReference, as well as point-of-care operations.
Recommended Story: How do buyers and sellers choose a strike price?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.